Dr Gisselbrecht also earned a molecular biology certificate from the University of Sciences Paris VII and an oncology certificate from Saint-Louis-Paris VII University. He is co-founder of the Groupe d’Etude des Lymphomes de l’Adulte (GELA), a French-Belgian cooperative group which has organized numerous randomized trials in lymphoma since 1984. He has been president of the group until 2002. GELA has recently extended its activities and changed its name to LYSA (Lymphoma Study Association). Dr Gisselbrecht and his research group are currently undertaking prospective trials to investigate the combination of dose-intensive chemotherapy and monoclonal antibodies in lymphoma. Dr Gisselbrecht has been lead investigator of several major phase II and phase III clinical trials, which investigated the place of autologous stem cell transplantation in the treatment of lymphoma. Currently, he is chair of the international CORAL study on relapsed diffuse large B-cell lymphoma. His research interests include clinico-pathologic correlative studies in lymphoma, the pharmacology of novel antineoplastic agents, and stem cell transplantation. Dr Gisselbrecht is an active member of several European and American scientific societies and is an expert with the European Medical Agency (EMA) as well as several cancer research agencies. He has published over 300 peer-reviewed papers and several book chapters and is on the editorial board of a number of highly respected journals.